Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...
The Associated Press on MSN2d
Why getting your flu and COVID-19 vaccines before the holidays is a good ideaYes, you can get your flu and COVID-19 shots at the same time. Don’t call them boosters — they’re not just another dose of ...
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu ...
GlobalData on MSN2d
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccineThe FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.
Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback